Introduction {#s1}
============

Fracture, most often occurring in the hip, is identified as a complication of type 1 and 2 diabetes (Forsén et al., [@B5]). With economic growth, changing dietary patterns, and relatively reduced insulin secretory function, the age-standardized prevalence of diabetes in adults has been increasing, particularly in Asian and other developing countries (Rhee, [@B14]; NCD Risk Factor Collaboration (NCD-RisC), [@B12]). Strotmeyer et al reported old age as the most significant risk factor for fractures in patients with diabetes (Strotmeyer et al., [@B16]). Fractures caused substantial morbidity and mortality in elderly people, resulting in the frequent necessity for long-term care (Manton et al., [@B11]). In addition to population growth and aging, such an increase in the incidence of fractures has led to the awareness of fracture prevention in elderly populations, particularly high risk groups having diabetes (Gonnelli et al., [@B7]).

In addition to identifying the direct effects of diabetes, recent studies have shown that the use of antidiabetic agents is an independent risk factor for fractures in diabetes (Bazelier et al., [@B1]; Zhu et al., [@B18]). Thiazolidinediones (TZDs) are reportedly associated with an increased fracture risk (Zhu et al., [@B18]). A study investigated the association between fracture risk and other antidiabetic agents, including dipeptidyl peptidase-4 (DPP4) (Schwartz, [@B15]). The results of Majumdar et al and the TECOS trial revealed that sitagliptin use is not associated with an increased fracture risk (Majumdar et al., [@B10]; Josse et al., [@B8]). Additionally, in a nationwide cohort study, Choi et al reported that DPP4 inhibitors in combination with metformin may confer protective effects against fractures (Choi et al., [@B2]). Thus, till now, the association between sitagliptin use and an increased fracture risk is either neural or protective. The association between days of sitagliptin and fracture risks remained unknown. Further, since sitagliptin is a second line agent for diabetes control and it is expensive compared to other antidiabetic agents. Considering relatively high fracture rates in diabetic population, it remained unknown whether the medical costs of sitagliptin users after fracture is higher or lower compared with non-sitagliptin users after fracture. Therefore, we conducted a large nationwide controlled cohort study in Taiwan to investigate the possible fracture risks of sitagliptin users and medical costs after fractures of sitagliptin users.

Methods {#s2}
=======

Data source
-----------

This retrospective cohort study with secondary data analysis was conducted using the Longitudinal Health Insurance Database (LHID) 2000, a subset of the National Health Insurance Research Database (NHIRD) of Taiwan. The NHIRD includes information on nearly 99% of the 23.74 million persons in Taiwan and is managed and released by the National Health Research Institutes (NHRI) (Database NHIR, [@B3]). Briefly, the LHID2000 was created by randomly selecting 1,000,000 enrollees from the 2000 Registry for Beneficiaries of the NHIRD. The LHID2000 has been confirmed by the NHRI to be representative of Taiwanese residents. Diseases in the LHID2000 are defined on the basis of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes.

Data availability statement
---------------------------

The dataset used in this study is held by the Taiwan Ministry of Health and Welfare (MOHW). The Ministry of Health and Welfare must approve our application to access this data. Any researcher interested in accessing this dataset can submit an application form to the Ministry of Health and Welfare requesting access. Please contact the staff of MOHW (Email: stcarolwu\@mohw.gov.tw) for further assistance. Taiwan Ministry of Health and Welfare Address: No.488, Sec. 6, Zhongxiao E. Rd., Nangang Dist., Taipei City 115, Taiwan (R.O.C.). Phone: +886-2-8590-6848. All relevant data are within the paper.

Ethics statement
----------------

The NHIRD encrypts patient personal information to protect privacy and provides researchers with anonymous identification numbers associated with relevant claims information, including sex, date of birth, medical services received, and prescriptions. Therefore, patient consent is not required to access the NHIRD. This study was approved to fulfill the condition for exemption by the Institutional Review Board (IRB) of China Medical University (CMUH104-REC2-115-CR2). The IRB also specifically waived the consent requirement.

Patients
--------

Patients with type 2 diabetes (ICD-9-CM 250.x0 and 250.x2) aged 20 years and above between 2009 and 2012 were divided into 2 cohorts according to sitagliptin use. The sitagliptin cohort included patients who received sitagliptin therapy for at least 28 days, and the nonsitagliptin cohort comprised patients without any sitagliptin therapy. The date on which sitagliptin therapy was commenced was considered the index date. The index date for non-sitagliptin users was randomly appointed a month and day with the same index year of the matched sitagliptin users. Patients younger than 20 years, those having a history of fracture (ICD-9-CM 820--829), and those with incomplete age or sex information were excluded. Patients who received sitagliptin were matched (1:1 ratio) with those who did not receive sitagliptin therapy according to their propensity score (PS) through nearest neighbor matching, initially to the eighth digit and then as required to the first digit. Therefore, matches were first made within a caliper width of 0.0000001, and then the caliper width was increased for unmatched cases to 0.1. We reconsidered the matching criteria and performed a rematch (greedy algorithm) (Parsons, [@B13]). The PS was calculated using logistic regression to estimate the probability of treatment assignment, based on the baseline variables, namely the year of receiving sitagliptin therapy; age; sex; the adapted Diabetes Complications Severity Index (aDCSI); comorbidities of rheumatoid arthirits, osteoporosis, hypertension, hyperlipidemia, stroke, chronic obstructive pulmonary disease (COPD), cirrhosis, chronic kidney disease (CKD), depression, fibromyalgia, coronary artery disease, alcohol-related diseases, biliary stone, asthma, and peptic ulcer disease (PUD); and use of steroids, benzodiazepines (BZDs), TZDs (including pioglitazone, rosiglitazone), insulin, sulfonylureas (including cetohexamide, chlorpropamide, glibenclamide, glibornuride, gliclazide, glimepiride, glipizide, gliquidone, tolazamide, and tolbutamide), metformin, and other antidiabetic agents (including acarbose, exenatide, guar_gum, liraglutide, miglitol, mitiglinide, nateglinide, repaglinide). Additional sitagliptin users and non-sitagliptin users unmatched population were also showed in Table [1](#T1){ref-type="table"}.

###### 

Comparisons in demographic characteristics and comorbidities in type 2 diabetes mellitus patient with and without sitagliptin.

                                                         **Unmatched population**          **Propensity Score Matched**                                                 
  ------------------------------------------------------ -------------------------- ------ ------------------------------ ------ ---------- ------ ------ ------ ------ -------
  Age group                                                                                                                      \< 0.001                               0.93
  ≤49                                                    724                        13.6   4019                           22.2              201    13.7   204    13.9   
  50-64                                                  2,255                      42.5   6460                           35.7              578    39.5   568    38.8   
  ≥65                                                    2,332                      43.9   7601                           42.0              684    46.8   691    47.2   
  Age, year Mean (SD)[^\#^](#TN1){ref-type="table-fn"}   63.0                       12.4   60.9                           13.8   \< 0.001   63.5   12.7   63.5   12.5   0.97
  Sex                                                                                                                            0.23                                   0.79
  Female                                                 2,362                      44.9   7940                           43.9              636    43.5   629    43.0   
  Male                                                   2,929                      55.2   10140                          56.1              827    56.5   834    57.0   
  Mean aDCSI score (SD)                                  0.36                       2.18   0.40                           1.20   0.11       0.37   0.74   0.30   1.53   0.09
  Duration of diabetes                                   8.25                       3.88   1.31                           5.18   \< 0.001   7.27   3.76   7.24   3.65   0.84
  **COMORBIDITY**                                                                                                                                                       
  Rheumatoid arthritis                                   15                         0.28   44                             0.24   0.62       6      0.41   4      0.27   0.53
  Osteoporosis                                           525                        9.89   1471                           8.14   \< 0.001   140    9.57   159    10.9   0.25
  Hypertension                                           4,318                      81.3   11728                          64.9   \< 0.001   1176   80.4   1155   79.0   0.33
  Hyperlipidemia                                         4,079                      76.8   8094                           44.8   \< 0.001   1061   72.5   1051   71.8   0.68
  Stroke                                                 1,620                      30.5   5921                           32.8   0.002      460    31.4   478    32.7   0.48
  COPD                                                   1,036                      19.5   3159                           17.5   \< 0.001   321    21.9   303    20.7   0.42
  Cirrhosis                                              1,958                      36.9   5345                           29.6   \< 0.001   552    37.7   559    38.2   0.79
  CKD                                                    595                        11.2   900                            4.98   \< 0.001   158    10.8   148    10.1   0.55
  Depression                                             441                        8.30   956                            5.29   \< 0.001   135    9.23   128    8.75   0.65
  Fibromyalgia                                           1,607                      30.3   3060                           16.9   \< 0.001   421    28.8   442    30.2   0.39
  Coronary artery disease                                5,758                      31.9   2394                           45.1   \< 0.001   599    40.9   596    40.7   0.91
  Alcohol-related diseases                               446                        8.40   909                            5.03   \< 0.001   119    8.13   118    8.07   0.95
  Biliary stone                                          255                        4.80   465                            2.57   \< 0.001   67     4.58   66     4.51   0.93
  Asthma                                                 654                        12.3   1730                           9.57   \< 0.001   190    13.0   176    12.0   0.43
  PUD                                                    3,574                      67.3   9347                           51.7   \< 0.001   995    68.0   987    67.5   0.75
  **MEDICATION**                                                                                                                                                        
  Steroid                                                5,106                      96.1   15237                          84.3   \< 0.001   1396   95.4   1395   95.4   0.93
  BZD                                                    4,687                      88.3   13677                          75.7   \< 0.001   1260   86.1   1262   86.3   0.91
  TZD                                                    2,883                      54.3   1844                           10.2   \< 0.001   589    40.3   534    36.5   0.04
  Insulin                                                3,333                      62.8   5009                           27.7   \< 0.001   844    57.7   811    55.4   0.22
  Sulfonylureas                                          5,030                      94.7   10253                          56.7   \< 0.001   1336   91.3   1336   91.3   0.99
  Metformin                                              5,157                      97.1   9301                           51.4   \< 0.001   1375   94.0   1380   94.3   0.69
  Other antidiabetic                                     3,368                      63.4   2875                           15.9   \< 0.001   781    53.4   754    51.5   0.32
  The number of antidiabetic agents                                                                                              \< 0.001                               0.002
  0                                                      44                         0.83   7333                           40.6              31     2.12   44     3.01   
  1-3                                                    2,188                      41.2   8250                           45.6              774    52.9   792    54.1   
  4-6                                                    2,681                      50.5   2370                           13.1              571    39.0   581    39.7   
  ≥7                                                     398                        7.49   127                            0.70              87     5.95   46     3.14   

Chi-Square Test,

Student\'s t-test.

*aDCSI, adapted Diabetes Complication Severity Index*.

Outcome measurement
-------------------

All patients were followed from the index date to the incidence of fractures, withdrawal from the NHI program, or the end of 2013, whichever occurred first. Total outpatient and inpatient medical costs within 1-year period following fractures were also measured.

Variables of interest
---------------------

The mean numbers of days of sitagliptin treatment were divided into 3 categories by setting cutoff values on the basis of the first (110 days) and second quartiles (250 days). We evaluated diabetes severity according to the aDCSI, which was reported to be a useful tool for categorizing the severity of diabetic complications (Young et al., [@B17]). The progression of diabetes was defined as an annual increase in the aDCSI from the date of diagnosis to the end of follow-up. The four groups were defined based on quartiles. Four progression groups were defined on the basis of an annual increase in the score of less than 0.51, 0.51--1.00, 1.01--2.00, and more than 2.0. Different progression groups indicated slow, moderate, rapid, and very rapid progression.

Statistical analysis
--------------------

The sitagliptin and nonsitagliptin cohorts were unmatched and were matched according to the PS. To estimate the PS, a logistic regression model was used, in which the sitagliptin treatment status was regressed on the baseline characteristics listed in Table [1](#T1){ref-type="table"}. We described and compared the distributions of the demographic variables, comorbidities (%), and medications (%) between the 2 cohorts by conducting chi-squared tests. The mean ages and standard deviations (SDs) were obtained and examined using Student\'s *t*-test. We calculated the incidence density of fractures according to person-years in unmached cohort. We determined the overall incidence as well as the incidence stratified by sex, age group, comorbidities, medications, and follow-up time for sitagliptin and PS matched nonsitagliptin cohorts. Univariable and multivariable Cox proportional hazards models were used for estimating the hazard ratios (HRs) and 95% confidence intervals (CIs) of fractures for the sitagliptin cohort relative to the unmatched nonsitagliptin cohort and sitagliptin cohort relative to the PS matched nonsitagliptin cohort. Variable found to be significant in the univariable analysis were further examined in the multivariable analysis. Further analysis was performed to evaluate the risk of diabetes progression from the date of diagnosis to the end of follow-up in the 4 progression groups to determine whether diabetes progression can predict fracture risk. We also assessed the joint effects of sitagliptin and other antidiabetic agents on fracture events. Data were analyzed with SAS (Version 9.3 for Windows; SAS Institute, Inc., Cary, NC, USA). All statistical tests were conducted at the 2-tailed significance level of 0.05.

Results {#s3}
=======

We identified 5,311 sitagliptin users and 18 080 nonsitagliptin patients as the unmatched cohorts. In addition, 1,463 and 1,463 patients in the sitagliptin and nonsitagliptin cohorts according to the PS matched (Figure [1](#F1){ref-type="fig"}). The two unmatched cohorts were significantly difference in the baseline characteristics. The mean age of patients in the sitagliptin and PS matched nonsitagliptin cohorts was 63.5 (SD = 12.7) and 63.5 (SD = 12.5) years, respectively. Patients aged ≥65 years were 44.9 vs. 47.2% in sitagliptin and nonsitagliptin cohort. Both matched cohorts included more men than women (56.5 vs. 57.0%). The mean aDCSI was 0.37 ± 0.74 years in the sitagliptin cohort and 0.30 ± 1.53 years in the PS matched nonsitagliptin cohort. The major comorbidities and medications used in the 2 cohorts were hypertension (80.4 vs. 79.0%), hyperlipidemia (72.5 vs. 71.8%), PUD (68.0 vs. 67.5%), steroids (95.4 vs. 95.4%), sulfonylureas (91.3 vs. 91.3%), and metformin (94.0 vs. 94.3%). The mean follow-up period was 3.38 (*SD* = 1.19) and 3.30 (*SD* = 1.32) years in the sitagliptin and PS matched nonsitagliptin cohorts, respectively (data not shown). Most of the matched patients had the number of antidiabetic agents of 1--3 (52.9 vs. 54.1%).

![The enrolling process of this study.](fphar-09-00677-g0001){#F1}

Overall, the sitagliptin cohort had higher incidence density rates of fractures (44.6 per 1,000 person-years) than did the nonsitagliptin cohort (44.5 per 1,000 person-years), with a crude HR of 1.02 (95% CI = 0.85--1.24; Table [2](#T2){ref-type="table"}). Multivariable Cox proportional hazards regression analysis for the risk of fracture revealed a nonsignificantly higher risk in the sitagliptin cohort (adjusted HR \[aHR\] = 1.01, 95% CI = 0.83--1.22) than in the nonsitagliptin cohort. The risk of fracture was not significantly higher in the unmatched sitagliptin cohort than in the unmatched nonsitagliptin cohort (aHR = 1.03, 95% CI = 0.93--1.14). After all stratification, the relative risk of fracture was not significantly higher in the sitagliptin cohort than in the PS matched nonsitagliptin cohort (Table [3](#T3){ref-type="table"}).

###### 

Comparison of incidence densities of fracture and hazard ratio between type 2 diabetes mellitus patient with and without sitagliptin by unmatched population and Propensity Score Matched.

                                                         **Unmatched population**   **Propensity Score Matched**                                                                           
  ------------------------------------------------------ -------------------------- ------------------------------------------------------- ---------------------------------------------- ------------------
  **FRACTURE**                                                                                                                                                                             
  Event                                                  607                        4,500                                                   221                                            215
  Person-years                                           13,987                     117,247                                                 4,952                                          4,827
  Rate^\#^                                               43.4                       38.4                                                    44.6                                           44.5
  Crude HR (95% CI)                                      1(Reference)               1.18(1.08, 1.29)[^\*\*\*^](#TN4){ref-type="table-fn"}   1(Reference)                                   1.02(0.85, 1.24)
  Adjusted HR (95% CI)[^‡^](#TN3){ref-type="table-fn"}   1(Reference)               1.03(0.93, 1.14)                                        1(Reference)[^†^](#TN2){ref-type="table-fn"}   1.01(0.83, 1.22)

Rate^\#^, incidence rate, per 1,000 person-years; HR, relative hazard ratio;

Variable found to be significant in the univariable analysis were further examined in the multivariable analysis for the matched sample.

**Comorbidity‡:** Patients with any one of the comorbidities (including osteoporosis, hypertension, hyperlipidemia, stroke, COPD, cirrhosis, CKD, depression, fibromyalgia, coronary artery disease, alcohol-related diseases, biliary stone, asthma, PUD) were classified as the comorbidity group.

*p \< 0.001*.

###### 

Comparison of incidence densities of fracture and hazard ratio between type 2 diabetes mellitus patient with and without sitagliptin mellitus by demographic characteristics and comorbidity.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------
                                                    **Propensity Score Matched**                                                          
  ------------------------------------------------- ------------------------------ ------- ------ ----- ------- ------ ------------------ ------------------
  **SEX**                                                                                                                                 

  Female                                            125                            2,132   58.6   116   2,051   56.6   1.06(0.82, 1.37)   1.08(0.84, 1.40)

  Male                                              96                             2,820   34.0   99    2,776   35.7   0.97(0.73, 1.29)   0.95(0.72, 1.27)

  **STRATIFY AGE**                                                                                                                        

  ≤ 49                                              14                             732     19.1   19    747     25.5   0.74(0.37, 1.47)   0.63(0.30, 1.32)

  50-64                                             77                             2,060   37.4   76    1,972   38.5   0.97(0.71, 1.34)   0.99(0.72, 1.37)

  ≥65                                               130                            2,160   60.2   120   2,108   56.9   1.10(0.86, 1.42)   1.07(0.83, 1.38)

  **COMORBIDITY**[^‡^](#TN6){ref-type="table-fn"}                                                                                         

  No                                                1                              44      22.6   6     79      76.2   0.29(0.04, 2.45)   0.23(0.02, 3.19)

  Yes                                               220                            4,908   44.8   209   4,749   44.0   1.04(0.86, 1.26)   1.03(0.85, 1.24)

  **MEDICATION**                                                                                                                          

  **Steroid**\                                      8                              227     35.3   5     239     20.9   1.59(0.52, 4.86)   2.68(0.57, 12.7)
  NO                                                                                                                                      

  Yes                                               213                            4,725   45.1   210   4,588   45.8   1.01(0.83, 1.22)   1.00(0.82, 1.21)

  **BZD**                                                                                                                                 

  No                                                21                             710     29.6   23    707     32.6   0.89(0.49, 1.61)   0.89(0.48, 1.65)

  Yes                                               200                            4,242   47.2   192   4,121   46.6   1.04(0.85, 1.27)   1.03(0.84, 1.26)

  **TZD**                                                                                                                                 

  No                                                126                            2,822   44.6   126   3,007   41.9   1.06(0.83, 1.36)   1.06(0.82, 1.36)

  Yes                                               95                             2,130   44.6   89    1,821   48.9   0.96(0.72, 1.29)   0.92(0.68, 1.24)

  **INSULIN**                                                                                                                             

  No                                                88                             2,153   40.9   91    2,225   40.9   1.02(0.76, 1.37)   1.07(0.79, 1.45)

  Yes                                               133                            2,799   47.5   124   2,602   47.7   1.02(0.80, 1.31)   1.00(0.78, 1.29)

  **SULFONYLUREAS**                                                                                                                       

  No                                                14                             400     35.0   18    403     44.6   0.82(0.41, 1.64)   0.93(0.42, 2.05)

  Yes                                               207                            4,552   45.5   197   4,424   44.5   1.05(0.86, 1.27)   1.03(0.85, 1.26)

  **METFORMIN**                                                                                                                           

  No                                                13                             262     49.5   11    270     40.7   1.27(0.57, 2.84)   0.87(0.30, 2.58)

  Yes                                               208                            4,689   44.4   204   4,557   44.8   1.01(0.83, 1.23)   1.00(0.82, 1.22)

  **OTHER ANTIDIABETIC**                                                                                                                  

  No                                                83                             2,305   36.0   90    2,382   37.8   0.96(0.71, 1.30)   0.99(0.73, 1.34)

  Yes                                               138                            2,647   52.1   125   2,446   51.1   1.05(0.82, 1.34)   1.05(0.82, 1.34)

  **FOLLOW-UP TIME**                                                                                                                      

  ≤ 1 years                                         55                             1,411   39.0   62    1,391   44.6   0.87(0.61, 1.26)   0.87(0.60, 1.24)

  \>1 years                                         166                            3,541   46.9   153   3,437   44.5   1.09(0.87, 1.36)   1.07(0.86, 1.34)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------

Rate^\#^, incidence rate, per 1,000 person-years; HR, relative hazard ratio;

Variable found to be significant in the univariable analysis were further examined in the multivariable analysis.

**Comorbidity‡:** *Patients with any one of the comorbidities (including osteoporosis, hypertension, hyperlipidemia, stroke, COPD, cirrhosis, CKD, depression, fibromyalgia, coronary artery disease, alcohol-related diseases, biliary stone, asthma, PUD) were classified as the comorbidity group*.

The incidence and risk of fracture in the 2 cohorts were compared with respect to the aDCSI (Table [4](#T4){ref-type="table"}). The incidence increased with the aDCSI in both cohorts. After stratification by the aDCSI, the relative risk of fracture was not higher in patients with an aDCSI of 0.00--0.50, 0.51--1.00, or \>1.00.

###### 

Comparison of incidence densities of fracture and hazard ratio between type 2 diabetes mellitus patient with and without sitagliptin by aDCSI change.

               **Propensity Score Matched**                                                           
  ------------ ------------------------------ ------- ------ ----- ------- ------ ------------------- -------------------
  0--0.50      161                            3,674   43.8   172   3,657   47.0   0.95 (0.77, 1.18)   0.94 (0.76, 1.17)
  0.51--1.00   30                             938     32.0   27    886     30.5   1.10 (0.65, 1.86)   1.01 (0.58, 1.75)
  \>1.00       30                             340     88.2   16    285     56.2   1.54 (0.84, 2.82)   1.73 (0.89, 3.37)

Rate^\#^, incidence rate, per 1,000 person-years; HR, relative hazard ratio;

*Variable found to be significant in the univariable analysis were further examined in the multivariable analysis*.

Table [5](#T5){ref-type="table"} shows that patients with the highest annual mean number of days of sitagliptin treatment (cutoff value: ≥250 days) no exhibited a higher risk of fracture compared with sitagliptin nonusers.

###### 

Hazard ratio and 95% confidence intervals of fracture associated with annual mean the number of days, annual mean DDD (defined daily dose) or annual mean mg dose of sitagliptin exposure by Propensity Score Matched.

                                                ***N***   **No. of Events**   **Rate^\#^**   **Crude HR**   **95% confidence interval**   **Adjusted HR[^†^](#TN9){ref-type="table-fn"}**   **95% confidence interval**
  --------------------------------------------- --------- ------------------- -------------- -------------- ----------------------------- ------------------------------------------------- -----------------------------
  Fracture                                      --        --                  --             --             --                            --                                                --
  Non-use of sitagliptin                        1,463     215                 44.5           1              (Reference)                   1                                                 (Reference)
  Sitagliptin[^&^](#TN8){ref-type="table-fn"}   --        --                  --             --             --                            --                                                --
  \< 110 days                                   365       50                  38.8           0.89           (0.65, 1.21)                  0.89                                              (0.65, 1.21)
  110--250 days                                 369       46                  35.3           0.81           (0.59, 1.12)                  0.78                                              (0.57, 1.08)
  ≥250 days                                     729       125                 53.0           1.22           (0.97, 1.52)                  1.20                                              (0.96, 1.50)
  p for trend                                                                                0.21           0.28                                                                            

The annual mean the number of days is partitioned in to 3 segments by fist quartile and second quartile.

Rate^\#^, incidence rate, per 1,000 person-years; HR, relative hazard ratio;

*Variable found to be significant in the univariable analysis were further examined in the multivariable analysis*.

We analyzed the joint effects of sitagliptin and other antidiabetic agents on fracture risk (Table [6](#T6){ref-type="table"}). The risk of fracture was nonsignificantly higher in patients administered both sitagliptin and metformin (aHR = 0.94, 95% CI = 0.57--1.56) and those administered both sitagliptin and sulfonylureas (aHR = 0.94, 95% CI = 0.50--1.76) than in those not administered sitagliptin, metformin, or sulfonylureas. Moreover, the joint effects of sitagliptin plus TZDs and sitagliptin plus insulin on fracture risk were not significant.

###### 

Cox proportional hazard regression analysis for the joint effect of Sitagliptin and medications on fracture risk by Propensity Score Matched.

  **Variables**   **Event**       **Rate^\#^**   **Adjusted HR[^†^](#TN10){ref-type="table-fn"} (95% CI)**   ***P*-value[^&^](#TN11){ref-type="table-fn"}**   
  --------------- --------------- -------------- ----------------------------------------------------------- ------------------------------------------------ ------
  Sitagliptin     TZD             --             --                                                          --                                               0.49
  No              No              126            41.9                                                        1 (Reference)                                    --
  Yes             No              89             48.9                                                        1.08(0.81, 1.43)                                 --
  No              Yes             126            44.6                                                        1.07(0.81, 1.37)                                 --
  Yes             Yes             95             44.6                                                        1.00(0.76, 1.32)                                 --
  Sitagliptin     Sulfonylureas   --             --                                                          --                                               0.64
  No              No              11             40.7                                                        1 (Reference)                                    --
  Yes             No              204            44.8                                                        0.94(0.50, 1.76)                                 --
  No              Yes             13             49.5                                                        1.18(0.53, 2.66)                                 --
  Yes             Yes             208            44.4                                                        0.94(0.50, 1.76)                                 --
  Sitagliptin     Meformin        --             --                                                          --                                               0.47
  No              No              18             44.6                                                        1 (Reference)                                    --
  Yes             No              197            44.5                                                        0.91(0.55, 1.50)                                 --
  No              Yes             14             35.0                                                        0.71(0.35, 1.43)                                 --
  Yes             Yes             207            45.5                                                        0.94(0.57, 1.56)                                 --
  Sitagliptin     Insulin         --             --                                                          --                                               0.99
  No              No              91             40.9                                                        1 (Reference)                                    --
  Yes             No              124            47.7                                                        1.07(0.81, 1.42)                                 --
  No              Yes             88             40.9                                                        1.02(0.76, 1.37)                                 --
  Yes             Yes             133            47.5                                                        1.07(0.81, 1.41)                                 --

Rate^\#^, incidence rate, per 1,000 person-years;

Variable found to be significant in the univariable analysis were further examined in the multivariable analysis.

*P-value for interaction*.

The average one-year medical cost after a fracture was 7,287 (*SD* = 9881.1) US dollars in sitagliptin users and 200.2 (*SD* = 428.4) US dollars in non-sitagliptin users (*p* \< 0.001). The average one-year medical costs of sitaglitpin users without fracture was 120.2(*SD* = 213.5) US dollars.

Discussion {#s4}
==========

In this large nationwide representative cohort of insured patients with type 2 diabetes, longer sitagliptin use, and a mean treatment duration ≥250 days were associated with an increased fracture risk. Furthermore, our data revealed that sitagliptin had no interaction with TZDs, sulfonylureas, insulin, and metformin in increasing the risk of fracture. The progression of diabetes, defined as an annual increase in the aDCSI, although high, was not significantly related to fracture risk.

It is biologically plausible that sitagliptin promotes skeletal muscle regeneration. In a diabetic rat model, Glorie et al showed that sitagliptin could attenuate bone loss and increase bone strength (Glorie et al., [@B6]). Clinical evidence is lacking on similar bone protection effects of sitagliptin. Several trials and cohort studies on sitagliptin have yielded neutral results (Driessen et al., [@B4]; Majumdar et al., [@B10]; Josse et al., [@B8]). The results of Majumdar et al. ([@B10]), and the TECOS trial (Josse et al., [@B8]) revealed that sitagliptin is not associated with fracture in type 2 diabetes. In our study, sitagliptin was associated with an increased fracture risk in a specific group of patients while a mean treatment duration ≥250 days. Several possible explanations account for such an inconsistency between the previous (Majumdar et al., [@B10]; Josse et al., [@B8]) and present findings. First, the median follow-up duration was different in the study of Majumdar et al. ([@B10]) (2 years) and the TECOS trial (3 years). Second, the analyzed clinical variables were different. Although all 3 studies incorporated age, antidiabetic agents, CAD, and PAD as factors influencing fractures, the current study also identified retinopathy, metabolic disorders, nephropathy, and neuropathy as clinical variables and weighed these variables by using the DCSI (Young et al., [@B17]). Further, the unit for evaluating the effect of sitaglitpin on fracture risks is different. This study adapted mean duration of follow up which confered two clinical variables, including duration of follow up and compliance. Thus, we believe that our study design could provide a more objective evaluation of the association of sitagliptin with fracture risk. It is interesting to note that cut point of 250 days represents either fracture risk or fracture protection of sitaglitpin. That would be possible reason why previous studies showed the effects of fractures either neutral or protective.

Finally, the population in the study of Majumdar et al. ([@B10]) study was relatively young (median age: 52 years), and diabetes control in the TECOS trial (Josse et al., [@B8]) was reasonable; these factors are considered to be associated with low fracture risk and might account for a lower incidence of fracture in those study populations. In this study, we used LHID, a subset of the National Health Insurance Research Database (NHIRD) of Taiwan, which encompasses medical information of one million insured people extracted from NHIRD. Further, we used propensity matching strategy to match the study cohort and control cohort. We also provide demographic information of unmatched population which would help understand the difference in matched and unmatched population. The advantages of this database and analyzing strategy are that it enables longitudinal follow up of each insured person and nation-based investigation to minimize possible surveillance bias.

The pathophysiology of diabetes in association with fractures is complex; diabetes duration, vision, falls, neuropathy, underlying nephropathy, and concomitant antidiabetic agents are possible contributing factors. Thus, it is difficult to assess the effects of individual antidiabetic agents on fracture risk in type 2 diabetes. This large, retrospective cohort study could address most of these inherent problems by using propensity-matching methods and the DCSI (Young et al., [@B17]). The aDCSI enables adjusting for the severity of diabetes comorbidities. Thus, this study provides a relatively homogenous baseline for the comparing the risk of fracture in diabetes.

This study found that the average 1-year medical costs after fracture of sitagliptin users are higher than non-sitagliptin diabetic users. The possible reason might be the characteristics of sitagliptin users. Since sitagliptin is 2nd line agent for diabetes control, people who needed sitagliptin prescription would be worse diabetic control. Thus, sitagliptin users might cost much medical costs compared with non-sitagliptin users. Whether sitagliptin had direct effects on causing more complex fracture and difficult healing would need further studies and investigations.

However, the study has some limitations. First, information about individual risk factors for osteoporosis, including smoking, family history, vitamin D consumption, sun exposure, body frame size, exercise habits, alcohol use, and caffeine use, medical compliance, were unavailable in the database. Second, the study was conducted based on ICD-9-CM codes recorded in the NHIRD; thus, detailed information about the levels of hemoglobin A1c, testosterone, and estrogen were unavailable. However, we matched patients according to the aDCSI and hypoglycemic episodes to minimize bias. Third, we had no information about the bone mineral density (BMD) of each individual, including data on dual energy X-ray absorptiometry. However, patients with type 2 diabetes are reported to have a higher BMD than those without diabetes (Ma et al., [@B9]). Thus, the BMD might not be an appropriate indicator of fracture in diabetes. Fourth, most patients in this study were Taiwanese; thus, our findings should be cautiously applied to other populations. Finally, low evens and CKD patients might have lower duration of medications use would be possible limitations in this study, but this would not cause major bias of the results.

This study revealed that the sitagliptin for ≥ 250 days had a higher risk of fracture, irrespective of the aDCSI. The average one-year medical costs after fracture of sitagliptin users are significantly higher than non-sitagliptin diabetic users. This finding prompts clinical awareness of potential fracture risk in patients with diabetes receiving sitagliptin treatment, rather than discouraging the prescription of sitagliptin. In addition, we provided clear joint effect of sitagliptin with other anti-diabetic agents and medical costs after fracture in sitaglitpin users. From payer and societal perspective, it might be needed to reconsider the rules of using sitaglitpin in diabetes. Future studies with longer follow-up periods are required to validate our findings.
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